Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Medite Cancer Diagnostics, Inc. (MDIT)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
86.7
|
M
| |
-84
|
% ROE
|
| Market cap: |
|
| |
-39
|
% ROIC
|
|
Net debt:
|
$5.9
|
M
| |
|
|
|
EV:
|
$5.91
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($3.7)
|
M
| |
|
|
|
EBIT
|
($4.0)
|
M
| |
|
|
| EPS |
($0.16)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 6.8 | 9.2 | 9.9 | 11.0 | 10.0 | 0.2 | 0.0 | 0.0 |
| Revenue growth | -26.3% | -6.6% | -10.0% | 10.3% | 4929.3% | 725.0% | -20.0% | -31.8% |
| Cost of goods sold | 6.7 | 5.6 | 6.1 | 7.2 | 5.7 | 0.1 | 0.6 | 0.0 |
| Gross profit | 0.2 | 3.6 | 3.8 | 3.8 | 4.2 | 0.1 | -0.6 | 0.0 |
| Gross margin | 2.4% | 39.3% | 38.5% | 34.8% | 42.3% | 47.5% | -2500.0% | 96.7% |
| Selling, general and administrative | 8.1 | 0.2 | 5.9 | 2.8 | 1.1 | 1.0 | 1.7 | 1.7 |
| Research and development | 1.2 | 1.5 | 1.3 | 1.2 | 0.9 | 0.3 | 0.2 | 0.2 |
| EBIT | -6.5 | -1.7 | -0.6 | -0.4 | 0.3 | -1.3 | -2.6 | -1.9 |
| EBIT margin | -95.1% | -18.0% | -6.1% | -3.6% | 3.0% | -640.9% | -10633.3% | -6170.0% |
| Pre-tax income | -7.3 | -2.3 | -0.8 | -0.6 | 0.1 | -1.5 | -2.9 | -2.1 |
| Income taxes | -0.5 | -0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 6.7% | 5.8% | | | 26.0% | 0.0% | 0.0% | 0.0% |
| Net income | -6.9 | -2.3 | -0.9 | -0.8 | 0.1 | -1.8 | -3.1 | -2.4 |
| Net margin | -101.3% | -24.4% | -9.5% | -7.4% | 0.5% | -899.0% | -13091.7% | -7876.7% |
| |
| Diluted EPS | ($0.26) | ($0.11) | ($0.05) | ($0.04) | $0.00 | ($0.02) | ($0.05) | ($0.05) |
| Shares outstanding (diluted) | 26.4 | 21.4 | 20.2 | 18.1 | 14.7 | 72.2 | 58.2 | 45.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|